Understanding previous miscarriage, preterm birth, fetal growth restriction, stillbirth, cesarean delivery, and uterine abnormalities—and how evidence-informed preconception care can help prepare for future pregnancies.
Before planning another pregnancy, one of the most important questions a healthcare professional can ask is surprisingly simple:
What happened during your previous pregnancies?
Were there complications involving blood pressure, blood glucose, or fetal growth?
Was a baby born prematurely or at a low birth weight?
Was a pregnancy lost through miscarriage or stillbirth?
Did a previous delivery require a cesarean section?
And if complications occurred, was an underlying cause ever identified?
These questions matter because reproductive history can provide clinically meaningful information about future pregnancy risks.
A previous pregnancy represents more than a collection of medical records. It offers insight into how maternal physiology, reproductive anatomy, placental development, fetal growth, and other biological processes interacted under the demands of pregnancy.
In 2008, Stubblefield and colleagues published The Clinical Content of Preconception Care: Reproductive History in the American Journal of Obstetrics & Gynecology.
The authors examined how previous low-birth-weight deliveries, preterm births, fetal growth restriction, cesarean sections, miscarriages, stillbirths, and uterine abnormalities could inform preparation for subsequent pregnancies.
Their central argument was that identifying these risks before conception creates opportunities for investigation, treatment, counseling, and appropriate monitoring.
Nearly two decades later, advances in obstetric medicine have changed several recommendations.
Newer trials have clarified which interventions prevent recurrent preterm birth.
Genetic technologies have improved the evaluation of pregnancy loss.
Research has challenged some surgical treatments previously considered beneficial.
And professional guidelines increasingly emphasize individualized risk assessment and shared decision-making.
The most important principle remains:
Reproductive history helps inform future pregnancy care, but it does not determine reproductive destiny.
1. Why Reproductive History Matters Before Conception
Every pregnancy involves complex physiological adaptations.
Cardiovascular function changes to support increased blood flow.
Metabolic regulation adjusts to meet maternal and fetal needs.
The uterus, cervix, and placenta undergo substantial structural and functional changes.
Immune and endocrine systems participate in implantation and pregnancy maintenance.
Previous complications may reveal vulnerabilities involving one or more of these processes.
For example, a history of spontaneous preterm birth may influence cervical-length surveillance during a subsequent pregnancy.
A previous pregnancy complicated by fetal growth restriction may prompt closer evaluation of maternal vascular health and fetal growth.
Repeated miscarriages may warrant genetic or uterine assessment.
A previous cesarean delivery may influence pregnancy spacing and delivery planning.
However, previous complications can arise for different reasons.
Two women with histories of preterm birth may have entirely different underlying circumstances.
Consequently, reproductive history should guide investigation rather than automatically lead to a standardized treatment.
2. Low Birth Weight, Prematurity, and Fetal Growth Restriction Are Not Identical
One important distinction in the original AJOG paper involves the difference between low birth weight, premature birth, and fetal growth restriction.
These terms are related but describe different characteristics.
Low birth weight generally refers to a newborn weighing less than 2,500 grams, regardless of gestational age.
Preterm birth refers to delivery before 37 completed weeks of gestation.
Fetal growth restriction, or FGR, describes a fetus that is not achieving expected growth, commonly identified using ultrasound measurements.
A baby may have low birth weight because of premature delivery, impaired fetal growth, or both.
Similarly, not every small newborn experienced pathological growth restriction.
Some babies are constitutionally small and otherwise healthy.
Distinguishing these possibilities matters because the causes, recurrence risks, and preventive strategies may differ.
For example, recurrent spontaneous preterm labor may lead to one clinical investigation, while recurrent placental growth restriction may lead to another.
The original pregnancy records can help clarify which process occurred.
3. Previous Preterm Birth: An Important Predictor of Future Risk
A history of spontaneous preterm delivery is among the most important predictors of another spontaneous preterm birth.
The original AJOG article emphasized that recurrence risk tends to increase when previous births occurred at earlier gestational ages or when more than one preterm birth has occurred.
However, these probabilities are population estimates.
They do not determine the outcome of an individual pregnancy.
Preterm delivery can result from several pathways, including spontaneous labor, premature rupture of membranes, cervical insufficiency, inflammation, or medically indicated early delivery.
This distinction is clinically important.
A previous delivery caused by severe preeclampsia is different from one caused by spontaneous labor at the same gestational age.
Preconception assessment should therefore establish the circumstances surrounding the earlier delivery.
Relevant information may include gestational age, cervical findings, signs of infection, placental pathology, maternal health conditions, and whether labor began spontaneously.
4. How Progesterone Recommendations Have Changed Since 2008
One of the most significant updates concerns progesterone treatment for preventing recurrent preterm birth.
The 2008 AJOG article described promising findings involving intramuscular 17-alpha hydroxyprogesterone caproate, sometimes abbreviated 17-OHPC.
At the time, this intervention was considered an important advance.
However, subsequent research failed to confirm the expected benefit.
In April 2023, the U.S. Food and Drug Administration withdrew approval of Makena and its generic equivalents for prevention of recurrent preterm birth.
The decision followed evidence that the treatment had not demonstrated the anticipated clinical benefit.
In response, the American College of Obstetricians and Gynecologists updated its recommendations.
Intramuscular 17-OHPC is no longer recommended for preventing recurrent spontaneous preterm birth.
Vaginal progesterone may be considered in selected individuals with a shortened cervix.
However, vaginal progesterone has not been established as an effective alternative for every patient with a history of spontaneous preterm birth when cervical shortening is absent.
This is an important example of evidence-based medicine evolving.
A treatment that appears promising in an early trial may not demonstrate the same benefits when evaluated in larger or different populations.
Preconception counseling must reflect the current evidence rather than automatically repeat older treatment protocols.
5. Cervical Length and Risk Assessment
The cervix plays an important structural role in maintaining pregnancy.
A shortened cervix during the second trimester can be associated with increased risk of spontaneous preterm delivery.
Transvaginal ultrasound provides a standardized method for measuring cervical length.
In 2024, the Society for Maternal-Fetal Medicine published updated recommendations concerning short cervix management in individuals without a previous spontaneous preterm birth.
For an asymptomatic individual with a singleton pregnancy and cervical length of 20 mm or less before 24 weeks, vaginal progesterone is recommended.
For cervical lengths between 21 and 25 mm, treatment may be considered through shared decision-making.
Different recommendations apply when a patient has a history of spontaneous preterm birth, cervical dilation, or other specific circumstances.
Some individuals may benefit from cervical cerclage.
However, cervical cerclage is not routinely indicated for every shortened cervix.
The appropriate strategy depends on clinical history and pregnancy findings.
Importantly, routine cervical-length measurement before pregnancy does not substitute for the appropriate assessment during pregnancy.
6. Cervical Insufficiency and Previous Second-Trimester Loss
Cervical insufficiency describes a clinical condition in which the cervix cannot maintain pregnancy in certain circumstances, often involving relatively painless cervical dilation during the second trimester.
It can be associated with pregnancy loss or very early preterm birth.
However, diagnosis is challenging.
There is no single preconception laboratory test that definitively establishes cervical insufficiency.
The clinical history is therefore particularly important.
A previous pregnancy involving painless cervical dilation may prompt specialist assessment before conception.
Management options during a future pregnancy may include history-indicated or ultrasound-indicated cerclage in appropriate circumstances.
However, not every second-trimester loss results from cervical insufficiency.
Other possible explanations include infection, fetal abnormalities, placental complications, or spontaneous preterm labor.
Appropriate evaluation should avoid assuming that one mechanism explains every loss.
7. Fetal Growth Restriction: Understanding Maternal, Fetal, and Placental Factors
Fetal growth restriction can result from several different biological processes.
The original AJOG article organized potential causes into three major categories: maternal, fetal, and placental factors.
Maternal contributors may include hypertension, diabetes with vascular complications, certain autoimmune disorders, kidney disease, and other medical conditions.
Fetal factors can include chromosomal abnormalities, genetic disorders, or particular infections.
Placental factors may involve abnormalities affecting nutrient and oxygen delivery.
However, not every case has an identifiable cause.
In 2020, the Society for Maternal-Fetal Medicine published comprehensive FGR guidance, reaffirmed in 2024.
The organization emphasized that FGR represents the final manifestation of several possible maternal, fetal, and placental conditions.
The guidance defines FGR using an estimated fetal weight or abdominal circumference below the 10th percentile for gestational age.
However, additional findings are important for distinguishing severity and guiding care.
These can include growth trajectory, Doppler ultrasound findings, and relevant maternal or fetal conditions.
8. What Can Be Done Before Another Pregnancy After FGR?
A previous growth-restricted pregnancy should prompt review of the earlier medical and obstetric records.
Relevant information may include the infant's birth weight, gestational age, maternal blood pressure, metabolic conditions, and placental findings.
Preconception assessment may identify medical concerns that warrant management before another pregnancy.
For example, chronic hypertension or diabetes should receive appropriate treatment.
Smoking cessation is important because tobacco exposure is associated with impaired fetal growth.
Nutrition should support adequate energy and micronutrient intake.
However, nutritional supplementation should not be presented as a universal treatment for placental insufficiency.
The SMFM guideline specifically recommends against low-molecular-weight heparin solely for preventing recurrent fetal growth restriction.
Similarly, sildenafil and activity restriction are not recommended as treatments for FGR.
Some patients may qualify for low-dose aspirin because of their overall risk of preeclampsia, but this requires individualized obstetric assessment.
The highest-value approach is identifying relevant maternal conditions and arranging suitable monitoring during pregnancy.
9. Preeclampsia, Hypertension, and the Importance of Previous Pregnancy Complications
Reproductive history should include more than the final gestational age and birth weight.
A previous pregnancy complicated by preeclampsia or gestational hypertension may provide important information about future cardiovascular and obstetric risks.
Preeclampsia is a pregnancy-specific disorder involving hypertension and, in some cases, organ dysfunction.
Its causes are complex and involve maternal, placental, and vascular processes.
A previous history of preeclampsia increases the risk of recurrence, although the level of risk depends on the severity and timing of the previous condition.
Preconception planning may include evaluation of blood pressure, kidney function, relevant medications, and other cardiovascular risk factors.
For individuals at increased risk, low-dose aspirin may be recommended during a subsequent pregnancy.
However, aspirin should not be prescribed indiscriminately to every patient with a prior adverse pregnancy outcome.
Management depends on the specific history and established obstetric indications.
10. Previous Cesarean Delivery: Why the Operative Report Matters
A prior cesarean section is another important component of reproductive history.
The original AJOG article emphasized reviewing the operative report rather than relying exclusively on a patient's recollection.
This remains valuable.
The type of uterine incision may influence the possibility of attempting vaginal birth after cesarean delivery.
For example, a prior low-transverse uterine incision typically carries different implications from a classical vertical uterine incision.
The number of previous cesarean deliveries also matters.
Repeat cesarean deliveries are associated with increasing risks of certain complications, including placenta accreta spectrum.
Placenta accreta spectrum involves abnormal placental attachment and may cause severe hemorrhage during delivery.
Previous cesarean scars are particularly relevant when placenta previa or other placental risk factors are present.
However, having a previous cesarean section does not automatically mean that every subsequent delivery must be surgical.
The appropriate options should be discussed with an obstetric clinician.
11. VBAC and Trial of Labor After Cesarean
Vaginal birth after cesarean, commonly abbreviated VBAC, refers to a vaginal delivery following a previous cesarean birth.
A trial of labor after cesarean, or TOLAC, is an attempt to achieve vaginal delivery.
For appropriately selected individuals, successful VBAC can offer several benefits.
These may include avoidance of additional abdominal surgery and fewer complications associated with repeated cesarean procedures.
However, TOLAC involves the risk of uterine rupture.
The risk depends on several factors, including the previous uterine incision and obstetric history.
Not every individual is an appropriate candidate.
A successful VBAC and an unsuccessful TOLAC ending in cesarean also have different risk profiles.
The decision should consider the patient's preferences, medical circumstances, and the capabilities of the delivery facility.
Preconception counseling provides time to review these issues before another pregnancy begins.
12. Pregnancy Spacing: Why Timing Between Pregnancies Matters
The interval between pregnancies is another important consideration.
The interpregnancy interval describes the period between a delivery and conception of the next pregnancy.
This differs from the interdelivery interval, which measures the time between two births.
The original AJOG paper discussed the association between short intervals and increased risks of several complications.
Current ACOG guidance recommends avoiding interpregnancy intervals shorter than six months.
Patients should also receive counseling about the potential risks and benefits of conception before 18 months.
Short intervals have been associated with certain adverse outcomes, including preterm birth and maternal complications.
Among individuals with a previous cesarean section, shorter intervals may increase the risk of uterine rupture during a subsequent trial of labor.
However, the evidence is largely observational.
Personal circumstances, age, infertility history, and reproductive preferences may influence the appropriate timing.
Consequently, pregnancy spacing should be discussed through individualized counseling rather than imposed as an inflexible rule.
13. Miscarriage: Understanding Sporadic and Recurrent Pregnancy Loss
Miscarriage is a common reproductive experience.
Many early miscarriages involve chromosomal abnormalities that arise during formation of eggs or sperm or during early embryonic development.
These events are often sporadic.
A miscarriage does not necessarily mean that either parent has an ongoing health condition or that subsequent pregnancies will be unsuccessful.
However, repeated pregnancy losses may warrant further investigation.
The original 2008 AJOG article used a definition of recurrent pregnancy loss based on three consecutive miscarriages.
Contemporary recommendations have changed.
The 2026 American Society for Reproductive Medicine guidance defines recurrent pregnancy loss as two or more spontaneous pregnancy losses, excluding confirmed ectopic and molar pregnancies.
This includes pregnancies confirmed by appropriate urine or blood hCG testing.
Patients do not necessarily need to experience three consecutive losses before evaluation is considered.
14. What Has Changed in the Evaluation of Recurrent Pregnancy Loss?
The 2026 ASRM guidance emphasizes a more selective and evidence-informed evaluation.
When feasible, chromosome analysis of miscarriage tissue can help determine whether a loss involved a chromosomal abnormality.
This information may provide an explanation and guide future counseling.
Evaluation of uterine anatomy is also important.
Additional testing may be appropriate according to clinical history and findings.
However, many tests previously used in recurrent pregnancy loss evaluations lack adequate evidence of benefit.
These include routine inherited thrombophilia testing, broad immune panels, MTHFR testing, and certain other investigations.
Similarly, the presence of an unusual laboratory result does not establish that treating the result will prevent miscarriage.
The objective is to identify recognized causes and avoid interventions that have not demonstrated meaningful clinical benefits.
15. Chromosomal Testing: What Can It Tell Us?
One important cause of early pregnancy loss is embryonic aneuploidy.
Aneuploidy occurs when cells contain an abnormal number of chromosomes.
Some chromosomal abnormalities are incompatible with continued development.
Modern technologies can examine miscarriage tissue for many of these abnormalities.
Array-based chromosomal testing offers advantages over traditional karyotyping in certain circumstances.
For example, it does not require living cells to grow in culture.
It may also identify some genetic changes that conventional chromosome analysis cannot detect.
However, no single test identifies every possible genetic abnormality.
An abnormal result may provide a useful explanation for a loss.
A normal result does not guarantee that an undetected maternal, paternal, fetal, or placental condition caused the pregnancy loss.
Interpretation should occur within an appropriate clinical and genetic counseling framework.
16. Antiphospholipid Syndrome: An Important Treatable Cause in Selected Patients
Antiphospholipid syndrome, or APS, is an autoimmune condition associated with thrombosis and certain pregnancy complications.
It involves specific antiphospholipid antibodies and clinical criteria.
In appropriately diagnosed patients, APS may contribute to recurrent pregnancy loss.
The 2026 ASRM guidance recommends testing when the relevant clinical criteria are met.
For patients with obstetric APS, low-dose aspirin and heparin may improve pregnancy outcomes.
However, this does not mean that every miscarriage warrants anticoagulant treatment.
Routine aspirin or heparin is not recommended for unexplained recurrent pregnancy loss without an appropriate indication.
Similarly, inherited thrombophilia markers should not automatically be treated as causes of miscarriage.
The distinction between APS and common inherited clotting variants is clinically important.
Evidence-based treatment depends on an established diagnosis.
17. Progesterone and Recurrent Miscarriage: A Different Clinical Question
Progesterone is involved in maintaining the uterine environment during early pregnancy.
However, the benefits of progesterone supplementation depend on the clinical indication.
Progesterone used in early pregnancy after miscarriage is not the same intervention as progesterone used for prevention of spontaneous preterm birth.
These questions should not be conflated.
Current ASRM guidance recognizes that vaginal progesterone may be considered in selected patients with early-pregnancy bleeding and a history of recurrent pregnancy loss.
However, evidence does not support universal progesterone supplementation for every patient with previous miscarriage.
Similarly, a single serum progesterone value does not reliably identify which patients will benefit from supplementation.
Clinical decisions should involve the obstetric or reproductive specialist and consider the relevant history.
18. Stillbirth: Why Investigation Before Another Pregnancy Matters
Stillbirth is a devastating pregnancy outcome.
It can result from fetal, placental, maternal, infectious, or other causes.
Sometimes a cause remains uncertain even after appropriate investigation.
A history of stillbirth is associated with increased risk during subsequent pregnancies.
However, recurrence risk varies considerably according to the circumstances of the previous loss.
A prior stillbirth caused by a sporadic chromosomal abnormality may have different implications from one associated with maternal vascular disease or placental dysfunction.
This is why identifying the likely cause matters.
The 2008 AJOG paper emphasized the importance of reviewing previous records, pathology findings, and relevant investigations before another pregnancy.
That recommendation remains highly relevant.
19. Placental Pathology: What Can the Placenta Reveal?
The placenta is a complex organ responsible for supporting fetal growth through nutrient and gas exchange, endocrine activity, and other physiological functions.
Abnormalities involving placental circulation, inflammation, structure, or implantation may contribute to adverse pregnancy outcomes.
Following a stillbirth, pathological examination of the placenta can provide important diagnostic information.
The 2020 ACOG and Society for Maternal-Fetal Medicine consensus on stillbirth recommends evaluation involving placental examination, fetal autopsy when accepted, and genetic assessment.
In the Stillbirth Collaborative Research Network study cited by this guidance, placental pathology was considered useful in establishing a cause of death in approximately 64.6% of evaluated cases.
Fetal autopsy contributed useful information in approximately 42.4%.
However, these percentages describe the diagnostic value within the studied population.
They do not mean that every stillbirth has a placental cause.
For prospective parents planning another pregnancy after stillbirth, reviewing these records can be a meaningful first step.
20. Why Broad Clotting and Immune Panels Are Not Always Appropriate After Stillbirth
The original AJOG article discussed relatively broad thrombophilia investigations in selected stillbirth cases.
However, professional guidance has evolved.
Current ACOG guidance does not recommend routine testing for inherited thrombophilias during stillbirth evaluation.
Testing for antiphospholipid antibodies may be appropriate in selected cases, particularly unexplained stillbirth.
Similarly, broad immune testing should not be assumed to identify hidden causes of pregnancy loss.
Biological theories involving inflammation, immune regulation, and placental function are scientifically important.
But the presence of an association does not establish that a particular immune marker caused a pregnancy complication.
Routine testing must be supported by reliable interpretation and clinically useful interventions.
The objective is to avoid creating additional uncertainty through unvalidated testing.
21. Pregnancy After Stillbirth: Medical and Psychological Preparation
Planning pregnancy after stillbirth can involve substantial emotional complexity.
Some individuals wish to conceive again relatively soon.
Others require more time.
There is no single emotional response or preparation timeline that applies to everyone.
Appropriate care should include discussion of the previous evaluation, likely recurrence risk, and potential monitoring strategies.
Psychological support may also be helpful.
However, medical and psychological preparation should not be treated as competing priorities.
A person may feel emotionally ready while still requiring medical evaluation.
Another may be physically prepared but uncertain about the prospect of another pregnancy.
Individualized counseling should respect both experiences.
The purpose of preconception care is to support informed decisions without imposing arbitrary expectations about grief or recovery.
22. Uterine Anomalies: Understanding Reproductive Anatomy
Congenital uterine anomalies arise from differences in development of the Müllerian ducts and related reproductive structures.
Examples include septate, bicornuate, unicornuate, and didelphys uteri.
These conditions vary in anatomy and potential reproductive significance.
Some individuals have no symptoms and experience uncomplicated pregnancies.
Others may have higher risks of pregnancy loss, preterm birth, or fetal malpresentation.
The original AJOG article emphasized identifying uterine anomalies through imaging and considering surgical correction in certain circumstances.
Modern imaging techniques, particularly three-dimensional ultrasound, can help distinguish different uterine configurations.
This is important because conditions that may appear similar on basic imaging can have different implications.
A septate uterus, for example, is not the same as a bicornuate uterus.
Accurate diagnosis should precede decisions about treatment.
23. Uterine Septum Surgery: How Randomized Evidence Changed the Discussion
The 2008 AJOG article recommended hysteroscopic resection of a uterine septum in women with poor previous reproductive outcomes.
At the time, this recommendation relied largely on observational studies.
However, randomized evidence has since challenged assumptions about the intervention's benefits.
In 2021, investigators published Septum Resection Versus Expectant Management in Women With a Septate Uterus in Human Reproduction.
The international multicenter randomized trial included women with a uterine septum and histories of subfertility, pregnancy loss, or preterm birth.
Live birth occurred in 31% of participants assigned to septum resection and 35% assigned to expectant management.
The trial did not demonstrate improved live-birth rates with surgery.
However, it was relatively small and included participants with different reproductive histories.
Consequently, it may not fully answer whether selected subgroups benefit.
Current ASRM guidance supports discussing hysteroscopic septum incision in patients with recurrent pregnancy loss through shared decision-making.
It should not be presented as a procedure that guarantees improved reproductive outcomes.
24. Other Uterine Conditions That May Affect Pregnancy
Reproductive history may also prompt evaluation of acquired uterine abnormalities.
Examples include endometrial polyps, submucosal fibroids, and intrauterine adhesions.
These conditions can sometimes alter the uterine cavity.
However, their reproductive significance depends on characteristics such as location, size, severity, and clinical history.
For example, a fibroid that substantially distorts the endometrial cavity may be more relevant than a small fibroid located elsewhere.
Intrauterine adhesions may occur after particular uterine procedures or infections.
Diagnostic evaluation may involve transvaginal ultrasound, saline infusion sonography, hysteroscopy, or other imaging as appropriate.
However, detecting an anatomical finding does not automatically establish that surgical correction will improve pregnancy outcomes.
Treatment decisions should consider available evidence and individual circumstances.
25. How Reproductive History Connects With Metabolic Health
Previous pregnancy complications may reveal underlying cardiometabolic concerns that remain relevant after childbirth.
A history of gestational diabetes is associated with increased future risk of type 2 diabetes.
Hypertensive disorders of pregnancy are associated with increased future cardiovascular risk.
Some conditions may persist after pregnancy, while others resolve but remain important indicators for long-term health.
Preconception planning should therefore include review of previous metabolic and cardiovascular complications.
This may involve appropriate glucose testing, blood pressure assessment, medication review, and other clinical evaluations.
However, these findings also matter outside reproductive planning.
A woman who previously experienced gestational diabetes deserves appropriate long-term metabolic follow-up even if she never plans another pregnancy.
Pregnancy history can contribute valuable information to preventive healthcare across the lifespan.
26. Why Pregnancy Outcomes Cannot Be Reduced to One Root Cause
Reproductive complications often involve multiple interacting factors.
A preterm birth may involve inflammation, cervical changes, uterine activity, or other pathways.
Fetal growth restriction may involve maternal, fetal, or placental conditions.
Miscarriage may involve chromosomal abnormalities, uterine anatomy, or other factors.
Stillbirth can result from several distinct processes.
Consequently, identifying one abnormal biomarker does not necessarily explain the previous outcome.
For example, elevated inflammatory markers do not establish an infectious cause.
A positive autoantibody does not automatically demonstrate immune-mediated pregnancy loss.
And a hormonal variation does not necessarily indicate that hormone supplementation will prevent recurrence.
A comprehensive approach should consider possible mechanisms while distinguishing validated findings from hypotheses.
The goal is not to construct the most elaborate explanation.
It is to identify the most clinically useful explanation supported by available evidence.
27. When Should Patients Seek Specialist Evaluation?
Certain reproductive histories warrant assessment by a qualified obstetric, maternal-fetal medicine, or reproductive endocrinology specialist before another pregnancy.
Examples include previous very early preterm birth, recurrent miscarriage, stillbirth, severe fetal growth restriction, significant uterine abnormalities, or major pregnancy-related medical complications.
However, the need for specialist care depends on the circumstances.
A previous uncomplicated cesarean section may require counseling rather than extensive investigation.
A single early miscarriage often does not require the same workup as recurrent pregnancy loss.
Likewise, not every patient with a previous low-birth-weight infant requires the same tests.
The objective is appropriate escalation based on risk.
28. A Practical Preconception Reproductive History Assessment
A useful evaluation should document previous pregnancy events with enough detail to guide future care.
Previous pregnancies: Number of pregnancies, gestational ages, and outcomes.
Previous births: Birth weight, gestational age, mode of delivery, and neonatal complications.
Pregnancy complications: Preeclampsia, gestational diabetes, fetal growth restriction, placental abnormalities, or other relevant conditions.
Pregnancy losses: Number, timing, and available evaluations of miscarriages or stillbirths.
Cesarean history: Number of procedures and type of uterine incision when known.
Reproductive anatomy: Known uterine anomalies, fibroids, adhesions, or prior uterine surgery.
Medical conditions: Hypertension, diabetes, autoimmune disease, kidney disease, and other relevant diagnoses.
Medication history: Treatments that may require modification before pregnancy.
Pregnancy spacing: Timing since the previous delivery and future reproductive goals.
Psychological well-being: Concerns related to previous complications, grief, anxiety, or reproductive decision-making.
When available, reviewing actual medical records can provide substantially more information than relying on diagnostic labels alone.
29. Practical Steps Before Another Pregnancy
A reasonable preparation strategy may include the following priorities.
Review previous pregnancy records. Obtain relevant delivery summaries, operative reports, ultrasound findings, and placental or genetic evaluations.
Clarify the previous complication. Determine whether an earlier delivery involved spontaneous preterm labor, fetal growth restriction, or medically indicated premature delivery.
Evaluate recurrent pregnancy loss appropriately. Consider specialist assessment after two or more qualifying losses.
Review maternal medical conditions. Address relevant cardiovascular, metabolic, autoimmune, and other health concerns.
Discuss pregnancy spacing. Consider the risks, benefits, and individual circumstances affecting conception timing.
Review medications and preventive care. Ensure treatment decisions reflect current evidence and pregnancy-specific considerations.
Obtain appropriate specialist guidance. Consider maternal-fetal medicine, reproductive endocrinology, or other specialists when indicated.
Address modifiable health factors. Support nutritional adequacy, smoking cessation, appropriate physical activity, and other evidence-informed preventive measures.
Seek psychological support when useful. Previous reproductive complications can create meaningful emotional needs.
Develop an individualized pregnancy plan. Identify which monitoring or interventions may be appropriate during a future pregnancy.
These measures cannot eliminate every reproductive risk.
However, they can help prospective parents and their healthcare teams make better-informed decisions.
30. How This Research Informs Our Preconception Care
We recognize that a person's reproductive history provides valuable information about their broader health.
Previous pregnancy complications may reveal relevant cardiovascular, metabolic, endocrine, inflammatory, anatomical, or other clinical concerns.
Within our conscious conception and women's wellness philosophy, we emphasize understanding the individual's history before recommending interventions.
For example, a patient with previous gestational diabetes may benefit from appropriately coordinated metabolic health evaluation and lifestyle support.
Someone with a history of preeclampsia may require medical blood-pressure assessment and relevant cardiovascular follow-up.
A woman with recurrent miscarriage or previous stillbirth should receive appropriate specialist evaluation rather than generalized testing for hormones, infections, or immune markers.
Our services can support relevant aspects of nutrition, movement, sleep, stress management, and health education.
However, we recognize that the diagnosis and management of obstetric complications require qualified obstetric and reproductive specialists.
We do not present lifestyle interventions as replacements for treatments such as appropriate cervical surveillance, management of antiphospholipid syndrome, or medically indicated pregnancy monitoring.
We also distinguish between established clinical interventions and emerging scientific hypotheses.
For example, the biological importance of placental inflammation does not mean that an extensive inflammatory laboratory panel can identify or prevent every form of pregnancy loss.
Our objective is to support informed preparation and appropriate coordination within a comprehensive healthcare team.
The purpose of reviewing reproductive history is not to assign blame for previous complications. It is to understand what happened, identify meaningful opportunities for prevention, and support better-informed care in the future.
Conclusion: Your Reproductive History Is Information, Not Destiny
Previous pregnancies can reveal important information about future reproductive health.
A history of preterm birth may influence cervical surveillance and obstetric planning.
Previous fetal growth restriction may prompt evaluation of maternal and placental risk factors.
Cesarean delivery history can inform pregnancy spacing and delivery options.
Repeated miscarriages may warrant genetic and anatomical investigation.
And a previous stillbirth deserves careful review to identify possible causes and support preparation for another pregnancy.
Since the original 2008 AJOG publication, research has changed several important treatment recommendations.
Some interventions once considered promising have failed to demonstrate benefit in subsequent trials.
New genetic technologies have improved diagnostic capabilities.
And contemporary guidelines increasingly emphasize selecting tests and treatments according to individual clinical circumstances.
These developments reinforce the importance of scientific humility.
Not every complication has an identifiable cause.
Not every abnormal finding requires treatment.
And no preconception program can guarantee an uncomplicated pregnancy.
Nevertheless, a carefully documented reproductive history provides a foundation for more personalized, evidence-informed care.
The goal of preconception care is not to erase the uncertainty of pregnancy. It is to learn from previous experiences, address meaningful risks, and help prospective parents approach future pregnancies with greater understanding, preparation, and support.
Research References
Stubblefield PG, Coonrod DV, Reddy UM, et al. The clinical content of preconception care: reproductive history. American Journal of Obstetrics & Gynecology. 2008;199(6 Suppl 2)–S383. https://doi.org/10.1016/j.ajog.2008.10.048
American College of Obstetricians and Gynecologists. Updated Clinical Guidance for the Use of Progestogen Supplementation for the Prevention of Recurrent Preterm Birth. Practice Advisory. 2023; updated 2025. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/04/updated-guidance-use-of-progestogen-supplementation-for-prevention-of-recurrent-preterm-birth
Society for Maternal-Fetal Medicine. Consult Series #70: Management of Short Cervix in Individuals Without a History of Spontaneous Preterm Birth. 2024. https://publications.smfm.org/publications/560-society-for-maternal-fetal-medicine-consult-series-70/
Society for Maternal-Fetal Medicine. Consult Series #52: Diagnosis and Management of Fetal Growth Restriction. 2020; reaffirmed 2024. https://publications.smfm.org/publications/289-society-for-maternal-fetal-medicine-consult-series-52/
American Society for Reproductive Medicine. Recurrent Pregnancy Loss: A Committee Opinion. 2026. https://www.asrm.org/practice-guidance/practice-committee-documents/recurrent-pregnancy-loss-a-committee-opinion-2026/
Rikken JFW, Verhorstert KWJ, Emanuel MH, et al. Septum resection versus expectant management in women with a septate uterus: an international multicentre open-label randomized controlled trial. Human Reproduction. 2021;36(5):1260–1267. https://doi.org/10.1093/humrep/deab037
American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine. Management of Stillbirth. Obstetric Care Consensus No. 10. 2020. https://www.acog.org/clinical/clinical-guidance/obstetric-care-consensus/articles/2020/03/management-of-stillbirth
American College of Obstetricians and Gynecologists. Interpregnancy Care. Obstetric Care Consensus No. 8. 2019. https://www.acog.org/clinical/clinical-guidance/obstetric-care-consensus/articles/2019/01/interpregnancy-care
American College of Obstetricians and Gynecologists. Prepregnancy Counseling. Committee Opinion No. 762. 2019. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/01/prepregnancy-counseling